<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02696031</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457H2315</org_study_id>
    <nct_id>NCT02696031</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis</brief_title>
  <acronym>PREVENT</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to&#xD;
      placebo in patients with nr-axSpA at Week 16 as well as Week 52 and long term efficacy and&#xD;
      safety up to Week 104 followed by an optional 16-week randomized dose escalation treatment&#xD;
      period and a continuous treatment period for up to Week 208&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, double-blind, placebo-controlled study. Approximately 555 patients&#xD;
      were randomized to one of three treatment groups (secukinumab 150 mg Load, secukinumab 150 mg&#xD;
      No Load or placebo in a ratio of 1:1:1):&#xD;
&#xD;
        -  Group 1 (secukinumab 150 mg Load): secukinumab 150 mg (1 mL, 150 mg/mL) s.c. prefilled&#xD;
           syringe (PFS) at baseline (BSL), Weeks 1, 2 and 3, followed by administration every four&#xD;
           weeks starting at Week 4&#xD;
&#xD;
        -  Group 2 (secukinumab 150 mg No Load): secukinumab 150 mg (1 mL, 150 mg/mL) s.c. PFS at&#xD;
           BSL, placebo at Weeks 1, 2 and 3, followed by secukinumab 150 mg PFS administration&#xD;
           every four weeks starting at Week 4&#xD;
&#xD;
        -  Group 3 (placebo): placebo (1 mL) s.c. PFS at BSL, Weeks 1, 2, 3, followed by&#xD;
           administration every four weeks starting at Week 4 Based on the clinical judgment of&#xD;
           disease activity by the investigator and the patient, background medications, such as&#xD;
           NSAIDs and DMARDs, may have been modified or added to treat signs and symptoms of&#xD;
           nr-axSpA from Week 16 on.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 29, 2016</start_date>
  <completion_date type="Actual">March 11, 2021</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This was a randomized, double-blind, placebo-controlled study. Approximately 555 patients were randomized to one of three treatment groups (secukinumab 150 mg Load, secukinumab 150 mg No Load or placebo in a ratio of 1:1:1):&#xD;
Group 1 (secukinumab 150 mg Load): secukinumab 150 mg (1 mL, 150 mg/mL) s.c. prefilled syringe (PFS) at baseline (BSL), Weeks 1, 2 and 3, followed by administration every four weeks starting at Week 4&#xD;
Group 2 (secukinumab 150 mg No Load): secukinumab 150 mg (1 mL, 150 mg/mL) s.c. PFS at BSL, placebo at Weeks 1, 2 and 3, followed by secukinumab 150 mg PFS administration every four weeks starting at Week 4&#xD;
Group 3 (placebo): placebo (1 mL) s.c. PFS at BSL, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4 Based on the clinical judgment of disease activity by the investigator and the patient, background medications, such as NSAIDs and DMARDs, may have been modified or added to treat signs and symptoms of nr-axSpA from Week 16 on.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Proportion of TNF Naive Participants Who Achieved an ASAS 40 Response (Assessment of SpondyloArthritis International Society Criteria)</measure>
    <time_frame>Week 16</time_frame>
    <description>ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Proportion of TNF Naive Participants Who Achieved an ASAS 40 Response (Assessment of SpondyloArthritis International Society Criteria)</measure>
    <time_frame>Week 52</time_frame>
    <description>(Table 11-2) ASAS40 (Assessment of SpondyloArthritis International Society criteria) response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Participants Who Achieved an ASAS 5/6</measure>
    <time_frame>Week 16</time_frame>
    <description>The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) Over Time</measure>
    <time_frame>Week 16</time_frame>
    <description>The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) consists of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which is used to answer 6 questions pertaining to the 5 major symptoms of AS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36 (Short Form-36 Physical Component Summary) Physical Component Summary Over Time</measure>
    <time_frame>Week 16</time_frame>
    <description>The SF-36 (Short Form-36 Physical Component Summary) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients to Achieve a BASDAI 50 Response</measure>
    <time_frame>Week 16 and 52</time_frame>
    <description>The BASDAI 50 is defined as an improvement of at least 50% in the BASDAI compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sacroiliac Joint Edema</measure>
    <time_frame>Week 16 and 52</time_frame>
    <description>MRI assessment of the Sacroiliac Joint. The comparison of SIJ edema score at Week 52 between secukinumab 150 mg No Load vs.placebo (H19) and between secukinumab 150 mg Load vs. placebo (H32) using FAS2 were not tested at week 16, since the Week 52 MRI reading campaign was not performed until all patients had completed Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in High Sensitivity C-reactive Protein Over Time</measure>
    <time_frame>Week 16</time_frame>
    <description>high sensitivity C-reactive protein is measured as a marker of inflammation from blood samples during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BASFI (Bath Ankylosing Spondylitis Functional Index) Over Time</measure>
    <time_frame>Week 16</time_frame>
    <description>The BASFI (Bath Ankylosing Spondylitis Functional Index) is a set of 10 questions designed to determine the degree of functional limitation in those patients with AS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Participants Who Achieved an ASAS 20 Response</measure>
    <time_frame>Week 16</time_frame>
    <description>ASAS 20 response is defined as an improvement of ≥20% and ≥1 unit on a scale of 10 in at least three of the four main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ASQoL (Ankylosing Spondylitis Quality of Life Scores) Over Time - Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The ASQoL (Ankylosing Spondylitis Quality of Life scores) is an instrument to measure health-related quality of life among patients with Ankylosig spondylosrthritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients Who Achieved an Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Inactive Disease</measure>
    <time_frame>Week 52</time_frame>
    <description>The Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) inactive disease criteria are defined as a value below 1.3 of a composite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ASQoL (Ankylosing Spondylitis Quality of Life Scores) Over Time - Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>The ASQoL (Ankylosing Spondylitis Quality of Life scores) is an instrument to measure health-related quality of life among patients with Ankylosig spondylosrthritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sacroiliac Joint Edema - Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>MRI assessment of the Sacroiliac Joint. The comparison of SIJ edema score at Week 52 between secukinumab 150 mg No Load vs.placebo (H19) and between secukinumab 150 mg Load vs. placebo (H32) using FAS2 were not tested at week 16, since the Week 52 MRI reading campaign was not performed until all patients had completed Week 52</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">555</enrollment>
  <condition>Non-radiographic Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Secukinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Secukinumab 150 mg s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Secukinumab 150 mg s.c. no load</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly</description>
    <arm_group_label>Secukinumab</arm_group_label>
    <other_name>AINN457</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>AIN457</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>150 mg Secukinumab s.c. monthly</description>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_label>Secukinumab</arm_group_label>
    <other_name>AIN457</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Dose escalation to 300mg at Year 2</description>
    <arm_group_label>Secukinumab</arm_group_label>
    <other_name>AIN457</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant, non-nursing female patients at least 18 years of age&#xD;
&#xD;
          -  Diagnosis of axial spondyloarthritis according to Ankylosing SpondyloArthritis&#xD;
             International Society (ASAS) axial spondyloarthritis criteria&#xD;
&#xD;
          -  objective signs of inflammation (magnetic resonance imaging (MRI) or abnormal&#xD;
             C-reactive protein)&#xD;
&#xD;
          -  active axial spondyloarthritis as assessed by total Bath Ankylosing Spondylitis&#xD;
             Disease Activity Index &gt;=4 cm&#xD;
&#xD;
          -  Spinal pain as measured by Bath Ankylosing Spondylitis Disease Activity Index question&#xD;
             #2 ≥ 4 cm (0-10 cm) at baseline&#xD;
&#xD;
          -  Total back pain as measured by Visual Analogue scale ≥ 40 mm (0-100 mm) at baseline&#xD;
&#xD;
          -  Patients should have been on at least 2 different non-steroidal anti-inflammatory&#xD;
             drugs with an inadequate response&#xD;
&#xD;
          -  Patients who have been on a TNFα inhibitor (not more than one) must have experienced&#xD;
             an inadequate response&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with radiographic evidence for sacroiliitis, grade ≥ 2 bilaterally or grade ≥&#xD;
             3 unilaterally&#xD;
&#xD;
          -  Inability or unwillingness to undergo MRI&#xD;
&#xD;
          -  Chest X-ray or MRI with evidence of ongoing infectious or malignant process&#xD;
&#xD;
          -  Patients taking high potency opioid analgesics&#xD;
&#xD;
          -  Previous exposure to secukinumab or any other biologic drug directly targeting&#xD;
             interleukin-17 (IL-17) or IL-17 receptor&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Potsdam</city>
        <state>New York</state>
        <zip>13676</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leander</city>
        <state>Texas</state>
        <zip>78641</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maroochydore</city>
        <state>Queensland</state>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malvern East</city>
        <state>Victoria</state>
        <zip>3145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woolloongabba</city>
        <zip>QLD 4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <zip>A-1060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 11</city>
        <state>Czech Republic</state>
        <zip>148 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 2</city>
        <state>Czech Republic</state>
        <zip>128 50</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 5</city>
        <state>Czech Republic</state>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno-Zidonice</city>
        <state>CZE</state>
        <zip>61500</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <state>CZ</state>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Limoges cedex</city>
        <state>Haute Vienne</state>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boulogne Billancourt</city>
        <zip>92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chambray les Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monaco</city>
        <zip>98000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rouen Cedex</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cottbus</city>
        <zip>03042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22767</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Herne</city>
        <zip>44649</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Potsdam</city>
        <zip>14469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haifa</city>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kita-gun</city>
        <state>Kagawa</state>
        <zip>761-0793</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawachinagano</city>
        <state>Osaka</state>
        <zip>586-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo ku</city>
        <state>Tokyo</state>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo ku</city>
        <state>Tokyo</state>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Meguro</city>
        <state>Tokyo</state>
        <zip>153-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku ku</city>
        <state>Tokyo</state>
        <zip>162 8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torreon</city>
        <state>Coahuila</state>
        <zip>27000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Metepec</city>
        <state>Estado De Mexico</state>
        <zip>52140</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44160</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Culiacan</city>
        <state>MEX</state>
        <zip>80000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kongsvinger</city>
        <zip>2212</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moss</city>
        <zip>1538</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-218</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>61 113</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02 118</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04 305</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-224</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Almada</city>
        <zip>2801 951</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Braga</city>
        <zip>4710243</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1050-034</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ponte de Lima</city>
        <zip>4990 041</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saratov</city>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Elda</city>
        <state>Alicante</state>
        <zip>03600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <state>Andalucia</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bilbao</city>
        <state>Pais Vasco</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goteborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fribourg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westcliff-on-Sea</city>
        <state>Essex</state>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leytonstone</city>
        <state>London</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stoke on Trent</city>
        <state>Staffordshire</state>
        <zip>ST6 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Worthing</city>
        <state>West Sussex</state>
        <zip>BN11 2DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bath</city>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Doncaster</city>
        <zip>DN2 5LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Northampton</city>
        <zip>NN1 5BD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2016</study_first_posted>
  <results_first_submitted>June 30, 2020</results_first_submitted>
  <results_first_submitted_qc>August 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 7, 2020</results_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-radiographic spondyloarthritis</keyword>
  <keyword>axial spondyloarthritis</keyword>
  <keyword>Ankylosing Spondylitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT02696031/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT02696031/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 1583 patients were screened for this study, of which 555 patients (35.1%) were randomized. Overall, 1028 patients (64.9%) discontinued prior to screening phase completion, most due to screen failure (1000 patients, 63.2%).</recruitment_details>
      <pre_assignment_details>5% of participants discontinued before or at week 24</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Secukinumab, Load</title>
          <description>AIN457 150 mg s.c.</description>
        </group>
        <group group_id="P2">
          <title>Secukinumab, no Load</title>
          <description>AIN457 150 mg s.c. no load</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo s.c.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Week 24</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="185"/>
                <participants group_id="P2" count="184"/>
                <participants group_id="P3" count="186"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="177"/>
                <participants group_id="P3" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Week 52</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="185"/>
                <participants group_id="P2" count="184"/>
                <participants group_id="P3" count="186"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="165"/>
                <participants group_id="P3" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Secukinumab, Load</title>
          <description>AIN457 150 mg s.c.</description>
        </group>
        <group group_id="B2">
          <title>Secukinumab, no Load</title>
          <description>AIN457 150 mg s.c. no load</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo s.c.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="185"/>
            <count group_id="B2" value="184"/>
            <count group_id="B3" value="186"/>
            <count group_id="B4" value="555"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.1" spread="11.45"/>
                    <measurement group_id="B2" value="39.8" spread="11.68"/>
                    <measurement group_id="B3" value="39.3" spread="11.47"/>
                    <measurement group_id="B4" value="39.4" spread="11.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="161"/>
                    <measurement group_id="B4" value="488"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="167"/>
                    <measurement group_id="B4" value="508"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of TNF Naive Participants Who Achieved an ASAS 40 Response (Assessment of SpondyloArthritis International Society Criteria)</title>
        <description>ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain</description>
        <time_frame>Week 16</time_frame>
        <population>Subset of TNF naive patients</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab, Load</title>
            <description>AIN457 150 mg s.c.</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab, no Load</title>
            <description>AIN457 150 mg s.c. no load</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo s.c.</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of TNF Naive Participants Who Achieved an ASAS 40 Response (Assessment of SpondyloArthritis International Society Criteria)</title>
          <description>ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain</description>
          <population>Subset of TNF naive patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>week 16</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0197</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>2.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>week 16</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0146</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>2.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>week 16</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9165</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Proportion of TNF Naive Participants Who Achieved an ASAS 40 Response (Assessment of SpondyloArthritis International Society Criteria)</title>
        <description>(Table 11-2) ASAS40 (Assessment of SpondyloArthritis International Society criteria) response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain</description>
        <time_frame>Week 52</time_frame>
        <population>Subset of TNF naive patients</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab, Load</title>
            <description>AIN457 150 mg s.c.</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab, no Load</title>
            <description>AIN457 150 mg s.c. no load</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo s.c.</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of TNF Naive Participants Who Achieved an ASAS 40 Response (Assessment of SpondyloArthritis International Society Criteria)</title>
          <description>(Table 11-2) ASAS40 (Assessment of SpondyloArthritis International Society criteria) response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain</description>
          <population>Subset of TNF naive patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0017</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.35</ci_lower_limit>
            <ci_upper_limit>3.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.64</ci_lower_limit>
            <ci_upper_limit>4.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4062</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Participants Who Achieved an ASAS 5/6</title>
        <description>The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains</description>
        <time_frame>Week 16</time_frame>
        <posting_date>03/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) Over Time</title>
        <description>The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) consists of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which is used to answer 6 questions pertaining to the 5 major symptoms of AS</description>
        <time_frame>Week 16</time_frame>
        <posting_date>03/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SF-36 (Short Form-36 Physical Component Summary) Physical Component Summary Over Time</title>
        <description>The SF-36 (Short Form-36 Physical Component Summary) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions</description>
        <time_frame>Week 16</time_frame>
        <posting_date>03/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients to Achieve a BASDAI 50 Response</title>
        <description>The BASDAI 50 is defined as an improvement of at least 50% in the BASDAI compared to baseline.</description>
        <time_frame>Week 16 and 52</time_frame>
        <posting_date>03/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sacroiliac Joint Edema</title>
        <description>MRI assessment of the Sacroiliac Joint. The comparison of SIJ edema score at Week 52 between secukinumab 150 mg No Load vs.placebo (H19) and between secukinumab 150 mg Load vs. placebo (H32) using FAS2 were not tested at week 16, since the Week 52 MRI reading campaign was not performed until all patients had completed Week 52</description>
        <time_frame>Week 16 and 52</time_frame>
        <posting_date>03/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in High Sensitivity C-reactive Protein Over Time</title>
        <description>high sensitivity C-reactive protein is measured as a marker of inflammation from blood samples during the study</description>
        <time_frame>Week 16</time_frame>
        <posting_date>03/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BASFI (Bath Ankylosing Spondylitis Functional Index) Over Time</title>
        <description>The BASFI (Bath Ankylosing Spondylitis Functional Index) is a set of 10 questions designed to determine the degree of functional limitation in those patients with AS.</description>
        <time_frame>Week 16</time_frame>
        <posting_date>03/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Participants Who Achieved an ASAS 20 Response</title>
        <description>ASAS 20 response is defined as an improvement of ≥20% and ≥1 unit on a scale of 10 in at least three of the four main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain</description>
        <time_frame>Week 16</time_frame>
        <posting_date>03/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ASQoL (Ankylosing Spondylitis Quality of Life Scores) Over Time - Week 16</title>
        <description>The ASQoL (Ankylosing Spondylitis Quality of Life scores) is an instrument to measure health-related quality of life among patients with Ankylosig spondylosrthritis</description>
        <time_frame>Week 16</time_frame>
        <posting_date>03/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients Who Achieved an Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Inactive Disease</title>
        <description>The Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) inactive disease criteria are defined as a value below 1.3 of a composite</description>
        <time_frame>Week 52</time_frame>
        <posting_date>03/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ASQoL (Ankylosing Spondylitis Quality of Life Scores) Over Time - Week 52</title>
        <description>The ASQoL (Ankylosing Spondylitis Quality of Life scores) is an instrument to measure health-related quality of life among patients with Ankylosig spondylosrthritis</description>
        <time_frame>Week 52</time_frame>
        <posting_date>03/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sacroiliac Joint Edema - Week 52</title>
        <description>MRI assessment of the Sacroiliac Joint. The comparison of SIJ edema score at Week 52 between secukinumab 150 mg No Load vs.placebo (H19) and between secukinumab 150 mg Load vs. placebo (H32) using FAS2 were not tested at week 16, since the Week 52 MRI reading campaign was not performed until all patients had completed Week 52</description>
        <time_frame>Week 52</time_frame>
        <posting_date>03/2022</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from first dose of study treatment until end of study treatment up to week 52.</time_frame>
      <desc>An Adverse event is any sign or symptom that occurs during the study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Secukinumab 150 mg Load</title>
          <description>Secukinumab 150 mg Load</description>
        </group>
        <group group_id="E2">
          <title>Secukinumab 150 mg No Load</title>
          <description>Secukinumab 150 mg No Load</description>
        </group>
        <group group_id="E3">
          <title>Any Secukinumab</title>
          <description>Any Secukinumab</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo s.c.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendiceal mucocoele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Vaccination site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Viral tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arthroscopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Back disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acrochordon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Spinal claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>IgA nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bartholin's cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Cervix enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Endometrial disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="303" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="70" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="122" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="185"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="543"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Publications from a single-site are postponed until publication of the pooled clinical trial data (i.e., data from all sites) or disclosure of trial results in their entirety</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The proportion of patients who achieved an ASAS partial remission week 16 was an exploratory OM but was inadvertently registered as a secondary OM, and thus will not be reported.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharma AG</organization>
      <phone>1-888-669-6682</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

